Usted está a punto de salir de la página web de GSK

Este enlace lo llevará a un sitio web que no pertenece a GSK. GSK no recomienda, aprueba ni acepta responsabilidad por los sitios controlados por terceros.

Continuar

Regresar

Popup

Reporte de Evento Adverso o Queja de Producto 

Información médica

Once-Daily TRIUMEQ Makes Dosing and Administration Simple for Your Patients

Recommended dosing 1*†‡
(for adults and adolescents above 12 years of age weighing at least 40 kg)

One pill, once daily 

TRIUMEQ is indicated for the treatment of HIV-infected adults and adolescents above 12 years of age weighing at least 40 kg.

Before initiating treatment with abacavir-containing products, screening for carriage of the HLA-B*5701 allele should be performed in any HIV-infected patient, irrespective of racial origin. Abacavir should not be used in patients known to carry the HLA-B*5701 allele.

Convenient dosing regimen 1

Convenient dosing: one pill, QD; No time or food restrictions; no boosting/additional renal monitoring; few significant DDIs

For further information, please see the Summary of Product Characteristics.

*TRIUMEQ is a fixed-dose pill and should not be prescribed for patients requiring dose adjustments. Separate preparations of dolutegravir, abacavir, and lamivudine are available in cases where discontinuation or dose adjustment is required. 1
†TRIUMEQ is not recommended for patients with integrase inhibitor resistance. 1
‡TRIUMEQ is not recommended for co-administration with efavirenz, nevirapine, rifampicin, or tipranavir/ritonavir. 1

References:

  1. TRIUMEQ Summary of Product Characteristics.

TRIUMEQ, TIVICAY, ZIAGEN, EPIVIR, KIVEXA, EPZICOM, TRIZIVIR, COMBIVIR
son marcas registradas del grupo de compañías ViiV Healthcare